Pharma's good times are here, GlobalData revenue analysis shows

It is no secret that last year was a generally a positive one for the world’s largest biopharmaceutical companies, particularly those with COVID-19 vaccines.

But just how good it was has now been revealed by GlobalData, the data and analytics company, in analysis showing that, in 2021, the top 20 firms had an aggregate revenue of $846.8 billion and a growth of $166.4 billion over 2020.

But perhaps most telling is the finding that 13 of the top 20 players reported more than 10% year on-year (YoY) revenue growth from 2020 to 2021. Remarkably, as many as four reported YoY revenue growth in excess of 80%. These were BioNTech (Nasdaq: BNTX), Moderna (Nasdaq: MRNA), Pfizer (NYSE: PFE) and Regeneron Pharmaceuticals (Nasdaq: REGN).